Nanomix Enters into Distribution Agreement for the eLab
SAN LEANDRO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) — Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care (POC) diagnostics, today announced a new distribution agreement with Diaclinic SpA (“Diaclinic”), a medical distributor headquartered in Santiago, Chile. Diaclinic will market and distribute the Nanōmix eLab in the Republic of Chile.
Nanomix Expands Reach with Distribution Agreement
Nanomix Corporation is excited to announce its partnership with Diaclinic SpA to bring the Nanōmix eLab to the Republic of Chile. This new distribution agreement will allow Nanomix to expand its reach into the South American market and provide access to its innovative POC diagnostics technology to healthcare professionals and patients in Chile.
The Nanōmix eLab is a cutting-edge diagnostic tool that allows for rapid and accurate testing at the point of care. Its mobile and affordable design makes it an ideal solution for healthcare settings where time and resources are limited. By partnering with Diaclinic, Nanomix is able to leverage their expertise and established network to effectively market and distribute the eLab throughout Chile.
This distribution agreement marks a significant milestone for Nanomix Corporation as it continues to make strides in the development of advanced diagnostic technologies. The Company is dedicated to improving healthcare outcomes and patient access to quality diagnostics, and this partnership with Diaclinic will help further that mission.
Impact on Individuals
For individuals in Chile, the distribution of the Nanōmix eLab means increased access to fast and reliable diagnostic testing. This can lead to earlier detection of health conditions and more timely treatment, ultimately improving health outcomes for patients.
Global Implications
On a global scale, the partnership between Nanomix Corporation and Diaclinic SpA has the potential to influence the way POC diagnostics are distributed and utilized in healthcare systems around the world. By demonstrating the effectiveness and efficiency of the Nanōmix eLab in Chile, other countries may be inspired to adopt similar technologies to improve healthcare delivery.
Conclusion
The distribution agreement between Nanomix Corporation and Diaclinic SpA is a testament to the company’s commitment to advancing healthcare through innovative POC diagnostics. This partnership represents a significant step towards improving access to quality healthcare in Chile and has the potential to impact healthcare systems worldwide.
